Ranbaxy Laboratories, received the final approval in Canada to manufacture and market Ran-Simvastatin tablets from Health Canada, Therapeutic Products Directorate. The total generic market size of Simvastatin tablets in Canada is $CAD153 million.
Ranbaxy has got the approval for Ran-Simvastatin in 5, 10, 20 and 40 mg strengths, through its wholly-owned subsidiary Ranbaxy Pharmaceuticals- Canada Inc (RPCI), Gurgaon-based (RPCI) said in a statement.
“We look forward to marketing this organically developed product in all strengths that will be commercialised at an affordable price. Ran-Simvastatin represents the second approval granted to RPCI in July,” said Paul Drake, President RPCI.
On Monday, the Pharmaceutical firm had received approval from the Canadian drug regulator TPD to market and manufacture 'Ran-Amlodipine tablets', used in treating hypertensions.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app